G6PD and malaria: Currently there is still no international agreement on the frequency and type of G6PD deficiency, justifying the suspension of the use of PQ in the treatment of vivax malaria, but the implementation of drugs into malaria eradication programmes should go along with a more thorough assessment of the clinical burden of G6PD condition in each region.